Clinical Trials Logo
  1. Home
  2. Staphylococcus Aureus Bacteremia
  3. NCT04160468

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase — DISRUPT  

Staphylococcus Aureus Bacteremia Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis

Clinical Trial Summary

The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S. aureus) bloodstream infections (BSI), including right-sided infective endocarditis (IE). Patients will be randomized to receive a single intravenous dose of exebacase or placebo. Patients will receive SoCA selected by the investigators based on the protocol. Exebacase, a direct lytic agent, is an entirely new treatment modality against S. aureus. Exebacase is a recombinantly-produced, purified cell wall hydrolase enzyme that results in rapid bacteriolysis, potent biofilm eradication, synergy with antibiotics, low propensity for resistance, and the potential to suppress antibiotic resistance when used together with antibiotics. Exebacase represents a first-in-field, first-in-class treatment with the potential to improve clinical outcome when used in addition to SoCA to treat S. aureus BSI including IE.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04160468
Study type Interventional
Source ContraFect
Contact
Status Terminated
Phase Phase 3
Start date December 20, 2019
Completion date September 9, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05862025 - Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study). N/A
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Recruiting NCT00622882 - Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia N/A
Recruiting NCT06168474 - Evaluating Simplified Layered Consent for Clinical Trials N/A
Completed NCT03163446 - Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia Phase 2
Not yet recruiting NCT06336824 - Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia Phase 3
Completed NCT02357966 - A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus Phase 1/Phase 2
Terminated NCT03089697 - Phase IIa Clinical Study of N-Rephasin® SAL200 Phase 2
Recruiting NCT03514446 - Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia Phase 4
Not yet recruiting NCT04886284 - Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia Phase 2
Withdrawn NCT03761953 - Oritavancin for Staphylococcus Aureus Infections in Opioid Users Phase 4
Recruiting NCT06249451 - Staphylococcus Aureus Bacteraemia (SAB)-Support-Study N/A
Recruiting NCT02098850 - Staphylococcus Aureus Bacteraemia in Adults N/A
Completed NCT01701219 - Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia Phase 4
Recruiting NCT05137119 - Staphylococcus Aureus Network Adaptive Platform Trial Phase 4
Completed NCT03908086 - Bloodstream Infections in Patients With Rheumatoid Arthritis
Completed NCT03138733 - Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia Phase 3
Completed NCT02476487 - The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia N/A
Recruiting NCT05184764 - Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia Phase 1/Phase 2
Completed NCT01971762 - Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology N/A